A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Jann N. Sarkaria(Mayo Clinic in Arizona), Evanthia Galanis(Mayo Clinic in Arizona), Maciej M. Mrugała(Seattle Pacific University), Kurt A. Jaeckle(Jacksonville College), Kaisorn L. Chaichana(Jacksonville College), Rachael A. Vaubel(Mayo Clinic), Michael Teufel(Boehringer Ingelheim (United States)), Antonio Omuro(Johns Hopkins University), Maria Martinez‐García(Hospital Del Mar), Ian F. Parney(Mayo Clinic), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Rolf Grempler(Boehringer Ingelheim (Germany)), H. M. Ross, Raphael Hesse(Universität Ulm), Paul M. Clément(Universitair Ziekenhuis Leuven), Linda Pronk(Boehringer Ingelheim (Spain)), Terry C. Burns(Neurological Surgery)
Cited by 3
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k